ESPR250117C3000
- 0.03
- -0.01-25.00%
Esperion Therapeutics Newsroom
Goldman Sachs Upgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Raises Target Price to $4
Cantor Fitzgerald Initiates Esperion Therapeutics(ESPR.US) With Buy Rating, Announces Target Price $8
Cantor Fitzgerald Initiates Esperion Therapeutics at Overweight With $8 Price Target
Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $6
Esperion Therapeutics Price Target Maintained With a $6.00/Share by Needham
Esperion Therapeutics Analyst Ratings
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
Jefferies Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
Esperion Therapeutics Analyst Ratings
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
A Quick Look at Today's Ratings for Esperion Therapeutics(ESPR.US), With a Forecast Between $2.05 to $16
BofA Securities Maintains Esperion Therapeutics(ESPR.US) With Sell Rating
Esperion Therapeutics Analyst Ratings
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
JMP Securities Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $7
HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
Esperion Therapeutics Analyst Ratings
BofA Securities Maintains Esperion Therapeutics(ESPR.US) With Sell Rating